→  The COPD drug mar­ket is ex­pect­ed to grow dra­mat­i­cal­ly over the next decade, hit­ting $14.1 bil­lion by 2025, ac­cord­ing to Glob­al­Da­ta.  It was $9.9 bil­lion in 2015. The growth will be fu­eled by in­creased di­ag­noses as well as new bron­chodila­tor drug class­es and an­ti-eosinophilic bi­o­log­ics.

→  Valeant is sell­ing iN­o­va for $930 mil­lion. The com­pa­ny is sell­ing off as­sets in an at­tempt to re­duce large piles of debt ac­quired un­der pre­vi­ous CEO Mike Pear­son as he went on a deal-mak­ing spree. Pear­son was re­placed by Joseph Pa­pa last year.

→  CytRx an­nounced it plans to sub­mit a rolling NDA un­der sec­tion 505(b)(2) New Drug Ap­pli­ca­tion (NDA) for al­dox­oru­bicin, which has re­ceived or­phan drug des­ig­na­tion, in soft tis­sue sar­co­mas (STS). The drug flopped in 2016.

→  Ex­act Sci­ences Cor­po­ra­tion $EXAS is sell­ing 7m shares of com­mon stock at a pub­lic of­fer­ing price of $35 per share. It’s ex­pect­ed to close June 12.

The FDA hasn’t detected any potential safety signals, including for stroke, in people aged 65 years and older who have received Pfizer’s bivalent Covid booster, one senior official told members of the agency’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Thursday.

The update comes as the FDA and CDC investigate a “preliminary signal” that may indicate an increased risk of ischemic stroke in older Americans who received Pfizer’s updated shot.

The FDA has stopped use of another drug as a result of the new coronavirus variants. On Thursday, the agency announced that AstraZeneca’s antibody combo Evusheld, which was an important prevention option for many immunocompromised people and others, is no longer authorized.

The FDA said it made its decision based on the fact that Evusheld works on fewer than 10% of circulating variants.

Evusheld was initially given emergency authorization at the end of 2021. However, as Omicron emerged, so did studies that showed Evusheld might not work against the dominant Omicron strain. In October, the FDA warned healthcare providers that Evusheld was useless against the Omicron subvariant BA.4.6. It followed that up with another announcement earlier this month that it did not think Evusheld would work against the latest Omicron subvariant XBB.1.5.

Drug discovery and development player Evotec entered another licensing deal with Big Pharma — this time with J&J’s Janssen.

The companies put out word that they entered into a strategic collaboration and license agreement with each other that focuses on targeted immune-based cancer therapies, to be commercialized by Janssen.

According to a statement, the collaboration will hinge on Evotec’s integrated drug discovery and manufacturing capabilities. During the pre-clinical R&D phase, the companies will collaborate closely — and then Janssen will take on full responsibility for both clinical development and commercialization.

Magenta Therapeutics is pausing an early-stage clinical trial after a patient died. The death was deemed to be possibly related to its drug, MGTA-117.

The biotech said the pause of the Phase I/II trial is voluntary and gives it time to review all available data before deciding what to do next. It’s also reported the known information to the FDA.

The dose-escalation trial was designed to test whether MGTA-117, an antibody-drug conjugate, could serve as a more targeted alternative to high-intensity chemotherapy as a conditioning agent for cancer patients who are set to receive a stem cell transplant. It recruited patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.

Regeneron has won a patent case against Swiss pharma giant Novartis over the delivery system for its eye drug Eylea.

The US Patent Trial and Appeal Board ruled that Novartis’ pre-filled syringe for injecting its eye medication Lucentis was “unpatentable” and handed the victory to Regeneron and its AMD drug Eylea.

In the initial complaint in 2020, Novartis alleged to the US International Trade Commission that certain pre-filled syringes for the intravitreal injection, and ultimately Regeneron’s delivery system for Eylea, were infringing on Novartis’ patent. Regeneron filed a petition to review Novartis’ claims in 2021.